Catatan efek · kuartal yang diarsipkan
SPRY
ARS Pharmaceuticals, Inc. · Healthcare · Biotechnology
13Pemegang yang dilacak
-4Δ pemegang
17.49MSaham yang dipegang
$175.83MNilai yang dilaporkan
+1Posisi baru
−5Keluar
Input momentum (manajer yang sebanding):
keluasan pemegang -23.5% ·
aliran saham -18.0% ·
posisi baru bersih -20.0%
— formula
Distribusi luas — penurunan saham dan lebih sedikit pemegang
Semua angka kepemilikan: hanya manajer 13F yang dipantau, posisi saham biasa, periode pelaporan Q3 2025
Kepemilikan dari waktu ke waktu
| Kuartal | Pemegang | Δ | Saham | Nilai yang dilaporkan | Baru | Keluar |
|---|---|---|---|---|---|---|
| Q2 2026 | 74 | +1 | 32.54M | $260.86M | +8 | −7 |
| Q1 2026 | 76 | +2 | 39.92M | $320.66M | +9 | −7 |
| Q4 2025 | 74 | +1 | 37.60M | $438.08M | +2 | −1 |
| Q3 2025 | 13 | -4 | 17.49M | $175.83M | +1 | −5 |
| Q2 2025 | 14 | 0 | 19.24M | $335.74M | +1 | −1 |
| Q1 2025 | 11 | +2 | 5.28M | $66.41M | +2 | — |
| Q4 2024 | 9 | -2 | 6.14M | $64.82M | — | −2 |
| Q3 2024 | 10 | +2 | 3.52M | $51.10M | +3 | −1 |
| Q2 2024 | 8 | — | 1.67M | $14.24M | — | — |
Siapa yang memegangnya · Q3 2025
| # | Manajer | Saham | Δ saham | Nilai | Bobotnya | Dipegang | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (pasif) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | BlackRock ✦ (pasif) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | BlackRock ✦ (pasif) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | BlackRock ✦ (pasif) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 5 | BlackRock ✦ (pasif) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | BlackRock ✦ (pasif) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | BlackRock ✦ (pasif) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | BlackRock ✦ (pasif) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | BlackRock ✦ (pasif) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | BlackRock ✦ (pasif) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | BlackRock ✦ (pasif) | 4.83M | +9.2% | $48.55M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | The Vanguard Group ✦ (pasif) | 3.50M | +7.3% | $35.18M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | The Vanguard Group ✦ (pasif) | 3.50M | +7.3% | $35.18M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | The Vanguard Group ✦ (pasif) | 3.50M | +7.3% | $35.18M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 15 | The Vanguard Group ✦ (pasif) | 3.50M | +7.3% | $35.18M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 16 | The Vanguard Group ✦ (pasif) | 3.50M | +7.3% | $35.18M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 17 | State Street Global Advisors ✦ (pasif) | 2.90M | +31.9% | $29.10M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 18 | Citadel Advisors ✦ | 1.59M | -29.3% | $15.94M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 19 | Citadel Advisors ✦ | 1.59M | -29.3% | $15.94M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 20 | Geode Capital Management ✦ (pasif) | 1.51M | +12.2% | $15.13M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 21 | Geode Capital Management ✦ (pasif) | 1.51M | +12.2% | $15.13M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 22 | Goldman Sachs Group ✦ | 1.33M | — | $13.32M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | Goldman Sachs Group ✦ | 1.33M | — | $13.32M | 0.0% | n/c | 1 | SEC ↗ |
| 24 | Fidelity (FMR) ✦ | 742.51K | -52.6% | $7.46M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 25 | Fidelity (FMR) ✦ | 742.51K | -52.6% | $7.46M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 26 | Morgan Stanley ✦ | 700.41K | — | $7.04M | 0.0% | n/c | 1 | SEC ↗ |
| 27 | Morgan Stanley ✦ | 700.41K | — | $7.04M | 0.0% | n/c | 1 | SEC ↗ |
| 28 | Morgan Stanley ✦ | 700.41K | — | $7.04M | 0.0% | n/c | 1 | SEC ↗ |
| 29 | Morgan Stanley ✦ | 700.41K | — | $7.04M | 0.0% | n/c | 1 | SEC ↗ |
| 30 | Morgan Stanley ✦ | 700.41K | — | $7.04M | 0.0% | n/c | 1 | SEC ↗ |
| 31 | Morgan Stanley ✦ | 700.41K | — | $7.04M | 0.0% | n/c | 1 | SEC ↗ |
| 32 | Marshall Wace ✦ | 197.32K | +394.4% | $1.98M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 33 | Marshall Wace ✦ | 197.32K | +394.4% | $1.98M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 34 | Marshall Wace ✦ | 197.32K | +394.4% | $1.98M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 35 | Two Sigma Investments ✦ | 72.18K | Baru | $725,379 | 0.0% | New | 1 | SEC ↗ |
| 36 | JPMorgan Chase ✦ | 70.12K | — | $704,686 | 0.0% | n/c | 1 | SEC ↗ |
| 37 | JPMorgan Chase ✦ | 70.12K | — | $704,686 | 0.0% | n/c | 1 | SEC ↗ |
| 38 | JPMorgan Chase ✦ | 70.12K | — | $704,686 | 0.0% | n/c | 1 | SEC ↗ |
| 39 | JPMorgan Chase ✦ | 70.12K | — | $704,686 | 0.0% | n/c | 1 | SEC ↗ |
| 40 | JPMorgan Chase ✦ | 70.12K | — | $704,686 | 0.0% | n/c | 1 | SEC ↗ |
| 41 | JPMorgan Chase ✦ | 70.12K | — | $704,686 | 0.0% | n/c | 1 | SEC ↗ |
| 42 | JPMorgan Chase ✦ | 70.12K | — | $704,686 | 0.0% | n/c | 1 | SEC ↗ |
| 43 | JPMorgan Chase ✦ | 70.12K | — | $704,686 | 0.0% | n/c | 1 | SEC ↗ |
| 44 | D. E. Shaw & Co. ✦ | 34.22K | -40.4% | $343,901 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 45 | D. E. Shaw & Co. ✦ | 34.22K | -40.4% | $343,901 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 46 | T. Rowe Price ✦ | 33.79K | +23.4% | $340,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
"Bobot mereka" = porsi posisi dari total nilai ekuitas 13F yang dilaporkan manajer tersebut — ukuran keyakinan. ✦ = manajer yang dikurasi.
Pembeli baru
| Two Sigma Investments | $725,379 | 0.0% |
Telah keluar
| Adage Capital Partners | $30.15M | adalah 0.1% |
| Wellington Management | $25.01M | adalah 0.0% |
| Millennium Management | $15.32M | adalah 0.0% |
| Gotham Asset Management | $475,617 | adalah 0.0% |
| AQR Capital Management | $281,503 | adalah 0.0% |
Konteks pasar penuh: di SEMUA filer 13F (data terstruktur SEC, Q1 2026): 201 pemegang, 92.94M saham, $730.00M dilaporkan. Ini adalah periode berbeda yang lebih lama dibandingkan angka semesta yang dilacak di atas, dan keduanya tidak pernah dicampur.
Sering dimiliki bersama
Apa lagi yang paling sering dimiliki oleh pemegang efek ini yang dilacak — berdasarkan jumlah kepemilikan bersama, bukan hubungan fundamental.
Asal-usul data: Kepemilikan dari posisi saham biasa 13F yang telah diurai (semesta yang dipantau, set pembanding untuk perubahan); baris orang dalam dari Formulir 3/4/5; kepemilikan saham signifikan dari Jadwal 13D/13G; setiap pengajuan tertaut ke dokumen aslinya di SEC EDGAR.
Periode pelaporan: Q3 2025 ·
Metodologi ·
Dapatkan ini melalui API